Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings Inc (MEDP)
NASDAQ:MEDP
Earnings Data
Report Date
Apr 27, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
3.94Last Year’s EPS
3.67Same Quarter Last Year
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple clear strengths: robust revenue and EBITDA growth in Q4 and full year 2025, strong cash generation, aggressive share repurchases, a healthy backlog, and positive 2026 guidance. Key near-term challenges include a spike in cancellations (notably in metabolic programs), modest margin compression due to higher reimbursable costs, and elevated pass-through exposure that may moderate reported top-line cadence early in 2026. Management expects hiring above 2025 levels but plans to rely on improved retention and productivity to support margins, and guidance assumes normalized cancellation rates. On balance, the company's fundamental growth, cash flow, and shareholder return actions outweigh the transient operational headwinds discussed on the call.Company Guidance
Strong Revenue Growth (Q4 and Full Year 2025)
Q4 2025 revenue of $708.5M, up 32% year-over-year; full year 2025 revenue of $2.53B, up 20% versus 2024.
Robust Net New Business and Backlog
Q4 net new business awards increased 39.1% YoY to $736.6M, producing a net book-to-bill of 1.04. Ending backlog was approx. $3.0B, up 4.3% year-over-year, with ~$1.9B expected to convert to revenue in the next 12 months and a Q4 backlog conversion rate of 23.6%.
Profitability Expansion in Absolute Dollars
Q4 EBITDA of $160.2M, up 20% YoY (from $133.5M); full year EBITDA $557.7M, up 16.1% YoY. Q4 net income $135.1M (up 15.5% YoY) and full year net income $451.1M (up 11.6% YoY).
Improving EPS and Shareholder Returns
Q4 diluted EPS $4.67 vs $3.67 prior year; full year diluted EPS $15.28 vs $12.63 in 2024. Repurchased 2.96M shares in 2025 for $912.9M with $821.7M remaining under authorization.
Strong Cash Generation and Working Capital
Generated $192.7M in cash from operating activities in Q4; cash balance of $497M as of Dec 31, 2025; net DSO was negative 58.7 days (indicating favorable working capital).
2026 Guidance Indicates Continued Growth
2026 revenue guidance $2.755B–$2.855B (growth of 8.9%–12.8% vs 2025); 2026 EBITDA guidance $605M–$635M (+8.5%–13.9%); 2026 net income $487M–$511M and EPS $16.68–$17.50 (no share repurchases assumed in guidance).
Operational Plans for Controlled Headcount Growth and Productivity
Company expects hiring in 2026 above 2025 levels (mid- to high-single-digit growth) but still below revenue growth rate due to improved retention and productivity gains, supporting margin resiliency.
MEDP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MEDP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 09, 2026 | $530.35 | $446.05 | -15.90% |
Oct 22, 2025 | $546.74 | $596.61 | +9.12% |
Jul 21, 2025 | $308.88 | $477.73 | +54.67% |
Apr 21, 2025 | $288.99 | $282.28 | -2.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Medpace Holdings Inc (MEDP) report earnings?
Medpace Holdings Inc (MEDP) is schdueled to report earning on Apr 27, 2026, After Close (Confirmed).
What is Medpace Holdings Inc (MEDP) earnings time?
Medpace Holdings Inc (MEDP) earnings time is at Apr 27, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MEDP EPS forecast?
MEDP EPS forecast for the fiscal quarter 2026 (Q1) is 3.94.